Skip to main content
Abdeckung

 

Eckert & Ziegler Acquires 53,000 Square Feet Facility for Expansion of Contract Development and Manufacturing Services

11.10.2021 / Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) has received from the Berlin City Government a 66-year long-term lease for an industrial property with 53,000 square feet (5,000 square meters) of factory floor located at the north eastern city limit of Berlin. The group plans to use the facility for the expansion of its contract development and manufacturing services that it provides, among others, for a variety of cancer therapeutics and radio diagnostics. Up to 10 mm EUR will be invested during the next years into the renovation of the site, the set-up of new laboratories, production and clean rooms meeting Good Manufacturing Standards for the pharmaceutical industry, and the creation of high-tech workplaces. Due to its proximity to a thermal power station, the new site is expected to meet highest energy efficiencies. … more

Lighting up tumor cells

30.09.2021 / MDC PhD student Matthias Jürgen Schmitt is being honored with the Curt Meyer Memorial Prize of the Berlin Cancer Society for his achievements in cancer research. He employs molecular reporters to investigate how glioblastoma – the deadliest brain tumor of all – becomes resistant to therapies. … more

Nantes University Hospital Doses First Patients with Eckert & Ziegler’s Novel Ga-68 Imaging Agent PENTIXAFOR

27.09.2021 / The Centre Hospitalier Universitaire de Nantes (CHU), the French university hospital serving the greater Nantes/Saint-Nazaire metropolitan area, has started to dose first patients with PENTIXAFOR, an innovative imaging compound for the initial staging of cancer patients with symptomatic multiple myelomas. The Ga-68 based radio-diagnostic promises to significantly improve the patient management for early forms of the disease by identifying the optimal therapeutic alternative. … more

BR50: Strengthen the science metropolis Berlin

24.09.2021 / With a position paper developed under the umbrella of Berlin Research 50, the non-university institutions of Berlin emphasize what is important for science in Berlin. They state ten demands that should be implemented by the future senate to strengthen Berlin as science metropolis. … more

Downtime at the nerve cell’s protein factories

15.09.2021 / A team led by MDC researcher Marina Chekulaeva has figured out why protein production slows down in the nerve cells of people suffering from Charcot-Marie-Tooth disease. This discovery could lead to a new therapeutic approach, the scientists report in the journal "Nucleic Acids Research". … more

COVID-19: What is driving the escalating hyperinflammation

13.09.2021 / The severity of COVID-19 is primary result of a dysregulated immune response. A cellular stress response mechanism plays a major role in the derailed immune response: senescence, report Clemens Schmitt and his colleagues in “Nature“. This suggests novel treatment path. … more

Disease genes help early brain development

09.09.2021 / If the cerebral hemispheres of the forebrain fail to divide properly in an unborn child, this results in holoprosencephaly. An MDC team led by Annette Hammes has discovered candidate genes that can positively influence the severity of this congenital malformation of the forebrain, as the researchers now report in the journal Development. … more

Lab Meets Teacher addresses cell diagnostics, cancer and AI

02.09.2021 / The new edition of the MDC’s “Lab Meets Teacher – Digital” further education program begins in September. The eight online LMT training sessions will give teachers insights into the latest research topics and methods – such as single-cell analysis, which is expected to deliver new understanding of disease processes. … more

Johanna Quandt-Professorship for Kathrin de la Rosa

01.09.2021 / Stiftung Charité Foundation and the Berlin Institute of Health at the Charité are continuing their format for recruiting outstanding female scientists. MDC researcher Kathrin de la Rosa is among the four new Johanna Quandt Professors. The immunologist will continue to lead her research group here. … more

A cell atlas of the pediatric heart

30.08.2021 / After providing funding for single-cell analysis of adult hearts, the Chan Zuckerberg Initiative is now supporting the creation of a cell atlas of children’s hearts. An international team led by Christine Seidman of Harvard University and Norbert Hübner of the MDC is again among the funded networks. … more

Eckert & Ziegler Starts Technetium-99 Delivery in Brazil

28.08.2021 / Eckert & Ziegler (ISIN DE0005659700, TecDAX), has started the delivery of Technetium-99 generators in Brazil. The subsidiary Eckert & Ziegler Brasil Comercial Ltda. had recently received a license from the Brazilian health authority ANVISA as the first and only private company to import and distribute technetium generators. Two leading hospitals in the greater Sao Paulo area are among the first customers, and further orders have already been placed. … more

Slow version of the glutamate receptor AMPA discovered

17.08.2021 / The glutamate receptor AMPA was previously known for its lightning-fast transmission of excitation. All the more surprising, therefore, are the results that researchers from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin have now made: AMPA-receptors can also be extraordinarily slow. The discovery of the new type of receptor puts synaptic signaling in a whole new light. The groundbreaking findings were recently published in the journal Cell Reports. … more

Eckert & Ziegler with Strong First Half of 2021

12.08.2021 / Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), achieved a new record result in the first half of 2021 with a net profit of € 22.3 million or € 1.08 per share. Revenues of the Group amounted to € 89.5 million and were thus 7% above the previous year's level. … more

Understanding lung damage in patients with COVID-19

11.08.2021 / A severe course of COVID-19 disease is not caused by the direct destruction of the lung due to the multiplication of the virus. As researchers from Berlin report in the journal Nature Communications, inflammatory processes and the endothelium of the lung are involved. … more

A defective potassium channel disrupts the brain's navigation system

10.08.2021 / The potassium channel KCNQ3 is required for our brain to generate accurate spatial maps. In mice, defects in KCNQ3 function have measurable effects on the internal navigation system. … more

Eckert & Ziegler Receives Manufacturing Authorization for Thorium and Lutetium Compounds

09.08.2021 / Eckert & Ziegler Radiopharma GmbH in Braunschweig, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), has now received manufacturing authorization from the Lower Saxony authorities for several thorium and lutetium compounds in accordance with the German Medicines Act. This authorization enables Eckert & Ziegler to supply its customers in the pharmaceutical industry with therapeutic radioisotopes for clinical trials and beyond. The radioisotopes are the central active ingredients in a series of innovative cancer drugs that are currently being tested in advanced phases by numerous drug manufacturers. … more

Eckert & Ziegler Takes over Brazilian Isotope Specialists – Strengthening their Presence in South America

03.08.2021 / Eckert & Ziegler (ISIN DE0005659700, TecDAX) acquired Ambientis Radioproteção, based in Sao Paulo, Brazil, effective July 31st, 2021 via its subsidiary Eckert & Ziegler Brasil Isotope Solutions Ltda (EZBIS). The business with annual sales in the low single-digit million range and 24 employees and specialists have been integrated into EZBIS´s Special Transportation Business Unit. … more

Berlin start-up T-knife raises $110 million

03.08.2021 / T-knife, a spin-off from the MDC and Charité, has raised 110 million U.S. dollars from international investors. The Berlin-based biotech company is developing novel immunotherapies against cancer that focus on teaching a patient’s T cells to recognize and fight solid tumors. … more

Half Year Results Stronger than Expected; Eckert & Ziegler Increases Profit Forecast by approximately 20%

27.07.2021 / Based on initial, unaudited assessments, earnings of Berlin-based isotope specialists Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) for the half year ending 30 June 2021 are higher than expected. The consolidated result in the first half of the year came up to approximately 22 mm EUR (previous year: 13 mm EUR), in sum already exceeding 75% of the guidance given for the full business year. … more

Anton Henssen honored with Berlin science award

22.07.2021 / Dr. Anton Henssen, a scientist and physician at the ECRC, has received the Young Investigator Award of the 2020 Berliner Wissenschaftspreis for his cutting-edge research into childhood cancers. The award was presented by the Governing Mayor of Berlin at a ceremony on July 22 in front of the Rotes Rathaus. … more

The new old-fashioned way

16.07.2021 / When Rudolf Virchow started studying medicine in Berlin in October 1839, the theory of the four humors of antiquity was still the mainstay of medical belief. Barely two decades later, the textbooks had to be rewritten: Virchow, who had since received his doctorate in medicine, succeeded in showing that the entire human body consists of cells – tiny units that can undergo disease reflecting morphological alterations.. Virchow’s revolutionary “cellular pathology” offered an entirely new understanding of causes of disease. His teachings, valid to this day, laid the foundation for modern, science-based medicine. … more

A glitch in the heart’s protein factory

05.07.2021 / MDC researchers have discovered a previously unknown cause of cardiac hypertrophy. As they report in the journal “Genome Biology”, genetic variation results in heart cell ribosomes not working properly. This disrupts protein production, which in turn causes the heart to grow too large. … more

Probing deeper into tumor tissues

17.06.2021 / Researchers at the MDC, the BIH and Charité have developed methods for performing comprehensive analyses of fixed tumor tissue samples. These analyses make it possible to shed new light on the clinical course of various cancer types, as the team reports in Nature Communications. … more

Founder Kieback gets T-knife off to a flying start

15.06.2021 / Best-funded start-up in Germany’s biotech sector … more

$7 million to advance cardiovascular research

14.06.2021 / Diverse messenger RNAs are produced in cells by “alternative splicing.” The Leducq Foundation is now supporting a transatlantic network dedicated to investigating this process in heart muscle cells and how changes in this process contribute to disease. Professor Michael Gotthardt of the MDC and Professor Leslie Leinwand of the University of Colorado Boulder are coordinating the project. … more

Eckert & Ziegler: Affiliate Receives Additional NIAID Funding to Advance Pharmaceutical Development

08.06.2021 / Myelo Therapeutics GmbH, an affiliate of Eckert & Ziegler (ISIN DE0005659700, TecDAX) focused on developing medical countermeasures (MCM) and therapies for cancer supportive care, announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, extended their contract to advance the development of the new chemical entity Myelo001. The extension into year two of the three-year contract provides an additional $2 million to Myelo Therapeutics to develop clinical-stage Myelo001 as an oral formulation MCM for the treatment of Hematopoietic Acute Radiation Syndrome (H-ARS). The total contract, initially awarded in April 2020, is valued at up to $ 6.2 million over three years if all options are exercised. … more

Tracking RNA through space and time

07.06.2021 / A research team at the MDC has succeeded in tracking genes through space and time within a one-cell zebrafish embryo – even before cell division occurs. They have now described a method in the journal “Nature Communications” that may one day allow scientists to measure cell response to drugs, for example, in organoids. … more

Single cells, RNA and the future of medicine

02.06.2021 / Two events, three days: researchers, industry, policymakers and the public are invited to attend the LifeTime Conference 2.0 on June 16 and 17 and the Berlin Summer Meeting 2021 on June 18 to discuss the latest technologies, tools and methods to tackle disease. Both virtual events are free. … more

Eckert & Ziegler Granted Exclusive Distribution Rights by Telix Pharmaceuticals for Prostate Cancer Diagnostic

18.05.2021 / Eckert & Ziegler (ISIN DE0005659700, TecDAX) has signed an agreement with Telix Pharmaceuticals (Telix), an Australian-headquartered company, for the exclusive distribution of Illuccix® (Kit for the preparation of Ga-68 PSMA-11 injection) in Germany. Illuccix® is a preparation for imaging prostate cancer with positron emission tomography (PET), currently under review for regulatory approval in multiple markets worldwide, including Germany. … more

Eckert & Ziegler: Record Income Due to Sale of Division and Strong Core Business

17.05.2021 / One-off effects from the deconsolidation of the tumor irradiation business, a waning of the Corona slump, and continued strong demand in particular for pharmaceutical radioisotopes more than doubled net profit at Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700; TecDAX) in the first quarter of 2021. With sales revenues of 44 million EUR (PY: 44), the Berlin-based technology company posted a net profit of 13.8 million EUR, 8.8 million EUR more than in the same period of the previous year … more

Low levels of a simple sugar – a new biomarker for severe MS?

12.05.2021 / Researchers from the ECRC in Berlin, together with scientists from the United States and Canada, have discovered a sugar molecule whose levels are reduced in the blood of patients with particularly severe multiple sclerosis. Their discovery could pave the way for a new therapeutic approach, the team reports in medical journal JAMA Neurology. … more

LNDW-Podcast: "Wissenschaften als Antwort auf Fake News" (Folge 12)

07.05.2021 / Fake News und Lügen haben gerade in Pandemiezeiten Konjunktur, Fakten es dagegen in Zeiten großer Unsicherheiten schwer. Die Lüge fliegt, die Wahrheit humpelt hinterher, wusste schon der irische Satiriker Jonathan Swift. „Wissenschaft als Antwort auf Fake News“ ist Thema der zwölften Ausgabe des Inforadiopodcasts „Lange Nacht der Wissenschaften“. … more

Eckert & Ziegler Signs Long-Term Supply Agreement with Sirtex Medical on Yttrium-90 for Treating Liver Cancer

28.04.2021 / Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) and Sirtex Medical (Sirtex) have executed a long-term supply agreement for the use of EZAG’s Yttrium-90 in Sirtex SIR-Spheres® Y-90 resin microspheres for liver cancer. The arrangement has an initial term of five years and guarantees Eckert & Ziegler a substantial share of Sirtex’s rising global demand. It supplements the existing broad-based supply agreement that Sirtex and Eckert & Ziegler have been operating since 2009. The Eckert & Ziegler sales forecast for the 2021 financial year remains unaffected. … more

Eckert & Ziegler Acquires Direct Majority Stake in Drug Developer PENTIXAPHARM

16.04.2021 / Eckert & Ziegler Strahlen- und Medizintechnik AG today acquired several share packages from the founders of the drug developer PENTIXAPHARM GmbH. Together with another internal share transfer, Eckert & Ziegler AG will directly hold a total of about 83% of the shares in the Würzburg-based company as of closing of the transactions. The total cost for the three share packages amount to approximately EUR 30 million. About a quarter of the purchase price payments will be made in cash, the remainder in shares of Eckert & Ziegler AG, which the seller has committed to hold at least until the date at which an advanced clinical trial approval is expected. The management of PENTIXAPHARM, which holds the remaining 17% of PENTIXAPHARM shares, has been granted additional options to sell its remaining shares. … more

Large Molecules Transported into Living Cells: Researchers Achieve Breakthrough into Cell Interior

16.04.2021 / It is one of the big pharmacological questions: How do you get large functional biomolecules like proteins or antibodies into a living cell? … more

Eckert & Ziegler to Build cGMP Facility for Radiopharmaceutical Services in Berlin

14.04.2021 / Eckert & Ziegler is proud to announce that it is expanding its production site in Berlin, Germany, with a new production facility for the contract manufacturing of radiopharmaceuticals. This new cGMP clean room suite with a total area of around 270 m² will be a 21 CFR 211 compliant, radiopharmaceutical manufacturing facility dedicated to late stage investigational and commercial stage radiopharmaceuticals and be operational from the first quarter of 2022. Together with a new U.S. based cGMP facility, Eckert & Ziegler will be able to provide radiopharmaceutical development services to companies looking for Europe, US and worldwide contract manufacturing. … more

Eckert & Ziegler Receives Technetium Generator Licenses for Brazil

12.04.2021 / The Brazilian regulator ANVISA has provided Eckert & Ziegler Brasil Comercial Ltda., a fully owned subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), with a license to import and distribute technetium generators. This is the second license ever given to an organization in Brazil, and only the first one for a private company. Technetium generators are a core component for a nuclear imaging procedure called SPECT, which is used for the detection of medical abnormalities. In Brazil, the SPECT market has a volume of about 100 mm Euro annually. Eckert & Ziegler already services about 500 hospitals and clinics in this country with medical devices and radioisotopes, and hopes to start shipping SPECT products in the third quarter of 2021. … more

Fasting acts as diet catalyst

07.04.2021 / Those who need to change their eating habits to normalise their blood pressure should start with a fast. In the journal “Nature Communications”, MDC and ECRC scientists explain why patients can use it as a tool to improve their health in the long term. … more

Eckert & Ziegler: Dividend Proposal EUR 0.45 per Share. Profit Increase in 2020. Positive Outlook for 2021.

29.03.2021 / Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) achieved sales of EUR 176.1 million (previous year EUR 178.5 million) and a net profit of EUR 22.9 million (previous year EUR 22.0 million) in the 2020 financial year. Earnings per share amounted to EUR 1.11. Executive Board and Supervisory Board today resolved to propose to the Annual General Meeting the payment of a split-adjusted dividend in the amount of EUR 0.45 (previous year: EUR 0.42) per share entitled to dividend. … more

Dauntless, visionary, inspiring – Detlev Ganten turns 80

26.03.2021 / His career brought him to Montreal, Marrakech, Heidelberg, and Berlin. Detlev Ganten is a citizen of the world. His greatest impact has been in Berlin, where he founded the MDC, was the head of Charité, and initiated the World Health Summit. What motivates this determined fighter for science and global health? … more

Grand opening of the Käthe Beutler Building

24.03.2021 / The Käthe Beutler Building has opened. Germany’s Federal Research Minister, Berlin’s Governing Mayor, the Chairman of the Jewish Community of Berlin and many guests inaugurated it. Around 200 specialists will work at the BIH & MDC Center for Vascular Biomedicine medicine – for the benefit of patients. … more

Eckert & Ziegler Divests From Tumour Irradiation Business

14.03.2021 / Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) will divest its tumour radiation equipment (HDR) business. As a first step, it has sold 51% of the shares in BEBIG Medical GmbH, into which it had transferred the HDR business, to the Chinese company TCL Healthcare Equipment (TCL) in Shanghai today. … more